Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background And Aims: Chronic HBV infection exhausts HBV-specific T cells, develops epigenetic imprints that impair immune responses, and limits the effectiveness of immune checkpoint inhibitor monotherapy, such as anti-programmed cell death ligand-1 antibody (αPD-L1). This study aimed to determine whether the DNA methyltransferase inhibitor decitabine (DAC) could reverse these epigenetic imprints and enhance immune checkpoint inhibitor efficacy in restoring HBV-specific T cell responses.
Approach And Results: We investigated HBV-specific T cell responses by 10-day in vitro stimulation of peripheral blood mononuclear cells (PBMCs) from patients with chronic HBV infection. PBMCs were stimulated with HBV core-specific overlapping peptide pools and HLA-A*02-restricted peptides, core 18 and pol 455 . The immunomodulatory effect of the DAC/αPD-L1 combination was assessed by flow cytometry, and our analysis included clinical characteristics, ex vivo DNA methylation of PBMCs, and IFNγ plasma levels.Treatment with DAC/αPD-L1 enhanced HBV-specific CD4 + T cell responses in a significant proportion of 53 patients, albeit with some variability. This effect was independent of the HBcrAg levels. Ex vivo DNA methylation revealed hypermethylation of key genes, such as IFNG among DAC-responders versus non-responders, supported by altered ex vivo IFNγ plasma levels. Further analysis of HBV-specific CD8 + T cell responses in 22 HLA-A*02-positive patients indicated distinct response patterns between core 18 and pol 455 stimulation, with pol 455 -specific CD8 + T cells showing increased susceptibility to DAC/αPD-L1, surpassing the αPD-L1 monotherapy response.
Conclusions: The combination of DAC/αPD-L1 shows promise in improving HBV-specific T cell responses in vitro , highlighting the potential of remodeling exhaustion-associated epigenetic signatures to enhance HBV-specific T cell restoration and suggesting a novel immunotherapeutic avenue for chronic HBV infection.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/HEP.0000000000001202 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
T cells engineered to carry a high-affinity HBV-specific T cell receptor: a potent weapon against advanced HBV-related HCC.
Gut
September 2025
Department of Gastroenterology and Hepatology, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Engineered monoclonal antibody tobevibart enhances HBsAg capture by Fc receptor-positive cells and activates HBV-specific T cells.
J Hepatol
August 2025
Vir Biotechnology, Bellinzona, Switzerland. Electronic address:
Background & Aims: Effective immune targeting is likely essential for achieving functional cure of chronic hepatitis B (CHB). Tobevibart, a human monoclonal antibody against hepatitis B virus (HBV) surface antigen (HBsAg), neutralizes HBV and hepatitis delta virus (HDV). This study aimed to characterize effects of the engineered GAALIE Fc of tobevibart on HBV immune responses.
View Article and Find Full Text PDFClinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial.
Gut
August 2025
Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China
Background: SCG101 is an autologous T-cell therapy specifically targeting hepatitis B virus (HBV) using a natural, high-affinity T-cell receptor that is stably expressed.
Objective: We evaluated the safety, pharmacokinetics, pharmacodynamics and efficacy of SCG101 in patients with HBV-related hepatocellular carcinoma (HCC) in an investigator-initiated trial.
Design: Six human leucocyte antigen (HLA)-A*02:01-positive, serum hepatitis B surface antigen (HBsAg)-positive and hepatitis B e antigen-negative patients with advanced HBV-HCC, who had failed one to three prior systemic therapies, received SCG101 at doses of 5×10 or 1×10 TCR-T cells/kg three days after lymphodepletion.
Targeting Ferroptosis Restores the Antiviral Activity of CD8 T Cells During Chronic Hepatitis B Virus Infection.
Cell Mol Gastroenterol Hepatol
August 2025
State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Institute of Immunopharmaceutical Sciences, School of Pharmaceutical Sciences, Shandong University, Jinan, Shandong, China. Electronic address:
Background & Aims: CD8 T cells play a crucial role in antiviral immunity; however, hepatitis B virus (HBV)-specific CD8 T cells become dysfunctional during chronic HBV (CHB) infection. Blocking inhibitory pathways only partially restores efficient antiviral responses, suggesting that the mechanism underlying CD8 T-cell dysfunction is complicated. This study aimed to investigate whether HBV-specific CD8 T cells undergo ferroptosis, examine its correlation with T-cell dysfunction, and elucidate the underlying mechanism and potential intervention strategies.
View Article and Find Full Text PDFMVA-HBVac-A novel vaccine vector that allows pan-genotypic targeting of hepatitis B virus by therapeutic vaccination.
Mol Ther Nucleic Acids
September 2025
Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, 81675 Munich, Germany.
Therapeutic vaccination holds the promise to cure chronic hepatitis B virus (HBV) infection. We hypothesize that B cell, CD4, and CD8 T cell responses are necessary to overcome HBV-specific immune tolerance in chronic infection because they accompany the rare, spontaneous resolution of chronic HBV infection. Therefore, we designed the heterologous prime-boost vaccine in which virus-like particle vaccination stimulates B and helper CD4 T cells and primes cytotoxic effector CD8 T cells and a vector boost expands the T cell response.
View Article and Find Full Text PDF